| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCF-001 | Tetrandrine | >98%,Standard References |
|
| DC11929 | ME-344 | A novel mitochondrial and mTOR inhibitor with potent anti-cancer activity, inhibits leukemia cell lines with IC50 of 70-260 nM. |
|
| DC11721 | PF-06747775 | A potent, selective, irreversible EGFR mutants with IC50 of 12, 3, 4 and 5 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively. |
|
| DC7353 | ABT-751(E 7010) Featured | ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 μM in neuroblastoma and non-neuroblastoma cell lines, respectively. |
|
| DC3164 | BIBW2992-MA2 (Afatinib dimaleate) Featured | Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2. |
|
| DC8695 | Akt1 and Akt2-IN-1 | Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 (IC50 = 3.5 nM) and Akt2 (IC50 = 42 nM), with potent and balanced activity. |
|
| DC12072 | Alflutinib (AST2818 mesylate) Featured | Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.. |
|
| DC7324 | Amuvatinib (MP-470) Featured | Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. |
|
| DC10009 | Avitinib free base Featured | Avitinib is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. |
|
| DC10008 | Avitinib maleate Featured | Avitinib is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. |
|
| DC8472 | AZD-3759 Featured | AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. |
|
| DC1075 | AZD4547 Featured | AZD4547 is a novel selective FGFR inhibitor targeting FGFR1, FGFR2, and FGFR3 with IC50 of of 0.2 nM, 2.5 nM, and 1.8 nM, respectively. |
|
| DC10739 | AZD4635 Featured | AZD4635 is a novel adenosine 2A receptor (A2AR) inhibitor with a Ki of 1.7 nM. |
|
| DC7006 | AZD-9291(Osimertinib) Featured | AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM). |
|
| DC8462 | AZD-9291 mesylate (Osimertinib，Mereletinib) Featured | AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM). |
|
| DC8280 | BLU-9931 Featured | BLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM). |
|
| DC3138 | Canertinib dihydrochloride Featured | Canertinib dihydrochloride is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. |
|
| DC7383 | CH5424802(Alectinib) Featured | CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation. |
|
| DC8728 | CH5424802(Alectinib HCl) Featured | CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation. |
|
| DC7106 | Rociletinib (CO-1686) Featured | CO-1686 is a novel, irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M(IC50=21 nM). |
|
| DC10527 | Ciforadenant (CPI-444) Featured | CPI-444 is an orally administered antagonist of the adenosine A2A receptor. It is designed to block the action of adenosine that is produced by tumors. |
|
| DC7695 | Defactinib (VS-6063, PF-04554878) Featured | Defactinib is a potent, selective, and orally active FAK inhibitor with demonstrated tolerability and preliminary clinical activity working as a single agent as well as in combination with paclitaxel. |
|
| DC10100 | Defactinib hydrochloride Featured | Defactinib is a potent, selective, and orally active FAK inhibitor with demonstrated tolerability and preliminary clinical activity working as a single agent as well as in combination with paclitaxel. |
|
| DC8300 | Entrectinib (RXDX-101) Featured | Entrectinib (RXDX-101), a potent and selective small molecule inhibitor of TrkA/B/C, ROS1, and ALK kinases, has demonstrated early clinical activity when orally administered intermittently under fasting conditions. |
|
| DC2101 | Erlotinib free base Featured | Erlotinib (OSI-744; NSC 718781; R1415) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
|
| DC3139 | Erlotinib hydrochloride Featured | Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM. |
|
| DC7342 | Foretinib(XL880) Featured | Foretinib (GSK1363089; XL880; EXEL-2880; GSK089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM. Less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR. |
|
| DC2103 | Gefitinib (ZD1839) Featured | Gefitinib (Iressa, ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. |
|
| DC11543 | Glumetinib Featured | Glumetinib (SCC 244) is a novel potent and highly selective inhibitor of c-Met kinase with IC50 of 0.42 nM. |
|
| DC8491 | GSK2879552 Featured | GSK2879552 is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. |
|
